Literature DB >> 8402119

Extensive versus limited lymph node dissection for gastric cancer: a comparative study of 320 patients.

F Pacelli1, G B Doglietto, R Bellantone, S Alfieri, A Sgadari, F Crucitti.   

Abstract

To compare extensive with limited lymph node dissection in the surgical treatment of gastric cancer, 320 patients undergoing gastric resection during 1981-1990 were divided into two groups. Although patients undergoing extended lymphadenectomy (n = 157) had a longer operating time (P = 0.0001) and a greater intraoperative blood transfusion requirement (P = 0.009) than those receiving limited dissection (n = 163), the incidence of postoperative complications (22.3 versus 28.2 per cent, P = 0.13) and the hospital mortality rate (3.8 versus 7.4 per cent, P = 0.12) were similar in the two groups. The 5-year survival rate after curative resection (117 and 121 patients after extensive and limited lymph node dissection respectively) was 65.4 versus 50.1 per cent (P = 0.01): 85.9 versus 82.2 per cent for stage I disease (P = 0.60), 66.1 versus 57.8 per cent for stage II (P = 0.82) and 48.7 versus 29.8 per cent for stage III (P = 0.02). Multivariate analysis using the Cox model showed that the extent of lymphadenectomy was an independent prognostic factor for survival (P = 0.01). The results support the value of extensive lymph node dissection in the surgical treatment of gastric carcinoma.

Entities:  

Mesh:

Year:  1993        PMID: 8402119     DOI: 10.1002/bjs.1800800930

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  22 in total

1.  Prognostic factors in gastric cancer.

Authors:  F Pacelli; G B Doglietto; P Caprino
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

2.  Morbidity and mortality of laparoscopy-assisted gastrectomy with extraperigastric lymph node dissection for gastric cancer.

Authors:  Min-Chan Kim; Ghap-Joong Jung; Hyung-Ho Kim
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

Review 3.  Gastric cancer.

Authors:  P McCulloch
Journal:  Postgrad Med J       Date:  1996-08       Impact factor: 2.401

4.  Clinical trials of surgical treatment of malignant diseases.

Authors:  Mitsuru Sasako
Journal:  Int J Clin Oncol       Date:  2005-06       Impact factor: 3.402

Review 5.  On the road to standardization of D2 lymph node dissection in a European population of patients with gastric cancer.

Authors:  Roman Yarema; Giovanni de Manzoni; Taras Fetsych; Myron Ohorchak; Mykhailo Pliatsko; Maria Bencivenga
Journal:  World J Gastrointest Oncol       Date:  2016-06-15

Review 6.  Extended lymphadenectomy in gastric cancer: when, for whom and why.

Authors:  D H Roukos
Journal:  Ann R Coll Surg Engl       Date:  1998-01       Impact factor: 1.891

7.  Gallstone disease after extended (D2) lymph node dissection for gastric cancer.

Authors:  Tomotaka Akatsu; Masashi Yoshida; Tetsuro Kubota; Motohide Shimazu; Masakazu Ueda; Yoshihide Otani; Go Wakabayashi; Koichi Aiura; Minoru Tanabe; Toshiharu Furukawa; Yoshiro Saikawa; Shigeyuki Kawachi; Yukako Akatsu; Koichiro Kumai; Masaki Kitajima
Journal:  World J Surg       Date:  2005-02       Impact factor: 3.352

8.  Lymph node involvement in gastric cancer for different tumor sites and T stage: Italian Research Group for Gastric Cancer (IRGGC) experience.

Authors:  Alberto Di Leo; Daniele Marrelli; Franco Roviello; Marco Bernini; AnnaMaria Minicozzi; Simone Giacopuzzi; Corrado Pedrazzani; Luca Gian Baiocchi; Giovanni de Manzoni
Journal:  J Gastrointest Surg       Date:  2007-09       Impact factor: 3.452

9.  Radical surgery for gastric cancer in Singapore.

Authors:  T K Ti
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

10.  Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer.

Authors:  Antonios-Apostolos K Tentes; Sotirios K Markakidis; Charisios Karanikiotis; Aliki Fiska; Ioannis K Tentes; Vangelis G Manolopoulos; Thespis Dimitriou
Journal:  Langenbecks Arch Surg       Date:  2006-03-14       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.